Significant progress has been made in vaccine and antiviral research. A multivalent mRNA vaccine demonstrates protection against monkeypox in murine models, marking a notable advancement against zoonotic viral infections. High-resolution cryo-EM structures of Nipah virus polymerase provide detailed molecular insights to aid antiviral design against this highly pathogenic virus. Additionally, computational strategies have driven the design of vaccines targeting Trichomonas vaginalis, and a settled patent dispute clears a path for mRNA technology consolidation involving BioNTech, CureVac, and GSK.